Page 1

RECORDATI ● ● ● RECORDATI : 2021 FIRST NINE MONTHS RESULTS APPROVED REVENUE + 5.7 % , EBITDA + 2.1 % AND NET INCOME + 8.1 % THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES NEWS RELEASE Consolidated net revenue € 1,156.2 million , + 5.7 % ( + 8.6 % at constant exchange rate ) . Strong contribution from Eligard® , with revenue of € 59.4 million , and from the rare diseases portfolio , up by 20.2 % . EBITDA ( ¹ ) € 447.9 million , at 38.7 % of revenue , + 2.1 % . Operating income € 372.9 million , + 2.4 % . Net income € 296.4 million , + 8.1 % . Adjusted net income ( 2 ) € 313.4 million , -1.3 % . Net financial position ( 3 ) : net debt of € 714.7 million ; Free Cash Flow ( 4 ) of € 352.9 million , up by € 69.6 million . Shareholders ' equity € 1,445.1 million . Expect FY results in line with the objectives set at the start of the year , at the lower end of the range . Resolution to distribute an interim 2021 dividend of € 0.53 per share . Approved a share buy - back program to service the stock option plans . Milan , 28 October 2021 The Board of Directors of Recordati S.p.A. approved the Group's Interim Report at 30 September 2021 , representing additional voluntary financial reporting ( 4 ) . The Report was prepared using the assessment , measurement and recognition criteria prescribed by international accounting standards ( IFRS ) . The Group's Interim Report at 30 September 2021 will be available today at the company's offices and on the company's website ( www.recordati.it ) and can also be viewed on the authorised storage system 1Info ( www.1Info.it ) . Financial highlights Net revenue in the first nine months of 2021 was € 1,156.2 million , up by + 5.7 % ( + 8.6 % at constant exchange rate ) compared to the same period the previous year , reflecting an adverse currency exchange rate effect of around € 31.7 million and the contribution from the new product Eligard® for € 59.4 million ( acquired under license from Tolmar International Ltd. in January ) . Net of these effects , growth was at 3.2 % , which reflects the loss of exclusivity in 2020 of silodosin and pitavastatin and the impact of the pandemic , especially on seasonal flu medications in the first part of 2021. Growth in the rare diseases portfolio was significant at 20.2 % , thanks especially to the growth in Signifor® and Isturisa® , but also to the solid performance of the main products in the portfolio . International sales grew by 7.8 % . The third quarter showed a continued improvement with a 15.5 % growth in net revenue ( + 17 % at constant exchange rate ) compared to the same period in 2020 , which had been more significantly impacted by the restriction measures . RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A. Registered office VIA M. CIVITALI , 1 20148 MILAN , ITALY SHARE CAPITAL € 26,140,644.50 fully paid up BUS . REG . OF MILAN , MONZA , BRIANZA and LODI 00748210150 TAX CODE / VAT NO . 00748210150 TEL . +39 0248787.1 FAX +39 0240073747 ECONOMIC AND ADMINISTRATIVE INDEX MILAN 401832 Company subject to management and coordination by Rossini Luxembourg S.àr.l